BMS’ Rutstein joins Daiichi as head of oncology
Plus new CMO at Boehringer Ingelheim, and updates from Repertoire, Atsena, TAAV and more
Mark Rutstein joined Daiichi Sankyo Co. Ltd. (Tokyo:4568) as head of global oncology clinical development to advance the company’s portfolio of oncology medicines. Rutstein was most recently VP of oncology development at Bristol Myers Squibb Co. (NYSE:BMY), where he led late-stage immuno-oncology programs. He is also an alum of Amgen Inc. (NASDAQ:AMGN), Bayer AG (Xetra:BAYN) and Eli Lilly and Co. (NYSE:LLY).
Boehringer Ingelheim GmbH hired Lykke Hinsch Gylvin as CMO and head of global medicine. Gylvin joins from Novartis AG (SIX:NOVN; NYSE:NVS), where she was VP, global medical franchise head of neuroscience. She also held leadership roles at AstraZeneca plc (LSE:AZN; NASDAQ:AZN), Roche (SIX:ROG; OTCQX:RHHBY) and H. Lundbeck A/S (CSE:LUN)...